FDA Approves Pebrilzo (pertuzumab-qcay), a Biosimilar to Perjeta

Nov 17, 2026 - 02:00
 0  0
BENGALURU, India and BRIDGEWATER, N.J., United States: November 16, 2026 -- Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0